D441 Medical Dosage Calculations and Pharmacology - Set 1 - Part 1

Correct Answer: aPTT between sixty-five and one-hundred-five seconds

Option c is correct because heparin's therapeutic effect is monitored using aPTT, with a therapeutic range of sixty-five to one-hundred-five seconds, confirming adequate anticoagulation without excess bleeding risk. Option a is incorrect because INR of two to three is the therapeutic monitoring range for warfarin, not heparin, and the two drugs require entirely different lab monitoring approaches. Option b is incorrect because PT level is associated with warfarin therapy monitoring and is not the primary lab used to titrate heparin dosing or confirm its therapeutic effect. Option d is incorrect because platelet count monitors for heparin-induced thrombocytopenia as a complication, not for confirming that heparin has reached its therapeutic anticoagulation range.

Correct Answer: Administer vitamin K as the antidote

Option a is correct because vitamin K is the specific antidote for warfarin overdose, as warfarin works by antagonizing vitamin K to prevent synthesis of several clotting factors. Option b is incorrect because protamine sulfate is the antidote specifically for heparin overdose, not warfarin, and administering it in this scenario would not reverse warfarin's anticoagulant effect. Option c is incorrect because holding a heparin dose is irrelevant here since the patient is on warfarin, and this action would not address the elevated INR or active bleeding emergency. Option d is incorrect because while fresh frozen plasma may be used in severe cases, vitamin K is the first-line specific antidote for warfarin toxicity and should be prepared and given immediately.

Correct Answer: I can stop taking this medication once I feel better.

Option d is correct because warfarin for atrial fibrillation is typically lifelong therapy, and stopping it when feeling better significantly increases stroke and systemic clot risk. Option a is incorrect because reporting unusual bruising or bleeding demonstrates correct understanding of warfarin's primary side effect and the appropriate response to seek medical evaluation. Option b is incorrect because maintaining consistent vitamin K dietary intake is appropriate patient teaching, since fluctuations in vitamin K directly affect INR stability and warfarin's effectiveness. Option c is incorrect because understanding that warfarin prevents new clots but does not dissolve existing ones is accurate pharmacology knowledge and demonstrates correct understanding of the medication.

Correct Answer: Heparin-induced thrombocytopenia; discontinue heparin immediately

Option b is correct because the combination of dropping platelet count, paradoxical new clot formation, and heparin exposure strongly indicates heparin-induced thrombocytopenia, requiring immediate discontinuation of heparin. Option a is incorrect because red man syndrome is an infusion reaction to vancomycin characterized by flushing and rash, not by thrombocytopenia or new clotting in a patient receiving heparin. Option c is incorrect because warfarin toxicity presents with bleeding and elevated INR, not with thrombocytopenia and paradoxical new clotting while the patient is on an anticoagulant infusion. Option d is incorrect because while infection can cause thrombocytopenia, the combination of heparin exposure, significant platelet drop, and new clot formation specifically and classically indicates heparin-induced thrombocytopenia.

Correct Answer: Combined use significantly increases the risk of gastrointestinal bleeding

Option c is correct because NSAIDs like naproxen irritate the GI mucosa and inhibit platelet function, which combined with warfarin's anticoagulant effect dramatically raises the risk of GI bleeding. Option a is incorrect because naproxen does not decrease warfarin's anticoagulant effect; NSAIDs may actually enhance bleeding risk by potentiating anticoagulation through platelet inhibition mechanisms. Option b is incorrect because naproxen does not increase warfarin metabolism; some NSAIDs may actually increase warfarin effect by competing for protein binding sites, which would raise INR. Option d is incorrect because naproxen affecting potassium levels is not a clinically significant interaction with warfarin; the critical concern is combined mucosal irritation and anticoagulation causing GI hemorrhage.

Correct Answer: Hold the digoxin and notify the provider

Option a is correct because digoxin must be held when the apical pulse is below sixty beats per minute, and the provider must be notified since bradycardia signals possible toxicity risk requiring reassessment. Option b is incorrect because administering digoxin when the heart rate is below sixty can worsen bradycardia and increase the risk of life-threatening digoxin toxicity in an already compromised patient. Option c is incorrect because nurses do not independently reduce digoxin dosing without a provider order; the appropriate action is to hold the dose and contact the provider for further guidance. Option d is incorrect because rechecking after thirty minutes without holding the dose is unsafe; once the pulse is below sixty, the medication must be held and the provider notified before any action is taken.

Correct Answer: The patient is experiencing digoxin toxicity worsened by hypokalemia

Option d is correct because a digoxin level above two nanograms per milliliter indicates toxicity, and hypokalemia makes the heart more sensitive to digoxin, worsening toxicity with GI and visual disturbances. Option a is incorrect because nausea, anorexia, and yellow-green halos are classic signs of digoxin toxicity, not expected therapeutic side effects at a therapeutic digoxin level within normal range. Option b is incorrect because these symptoms do not represent an allergic reaction; they are specific toxicity signs directly tied to elevated digoxin levels combined with an electrolyte imbalance. Option c is incorrect because low potassium is directly related to digoxin toxicity risk; hypokalemia increases cardiac muscle sensitivity to digoxin, making toxicity far more likely and more dangerous.

Correct Answer: Swelling of the face, lips, or tongue after the first dose

Option b is correct because angioedema, characterized by swelling of the face, lips, and tongue, is a life-threatening adverse effect of ACE inhibitors like lisinopril requiring immediate medical attention. Option a is incorrect because mild dizziness upon standing is orthostatic hypotension, a common and expected first-dose side effect of ACE inhibitors that is monitored but is not a medical emergency. Option c is incorrect because a dry persistent cough is a common non-dangerous side effect of ACE inhibitors caused by bradykinin accumulation; it is uncomfortable but does not require emergency reporting. Option d is incorrect because mild fatigue in the first weeks of antihypertensive therapy is a common adjustment response and does not represent a dangerous adverse reaction requiring immediate provider notification.

Correct Answer: Hold the metoprolol and notify the provider immediately

Option c is correct because beta blockers like metoprolol can cause bronchospasm in asthma patients by blocking beta-2 receptors in the lungs, making this a contraindicated situation requiring immediate action. Option a is incorrect because giving more metoprolol would worsen bronchospasm in an asthma patient, as beta blockers inhibit bronchodilation and are contraindicated in patients with reactive airway disease. Option b is incorrect because worsening bronchospasm is a serious adverse reaction requiring immediate intervention, not routine monitoring; a delay could result in life-threatening respiratory compromise. Option d is incorrect because while albuterol may temporarily help, the root cause is the beta blocker itself, which must be held and reported rather than continued alongside a bronchodilator.

Correct Answer: Spironolactone causes potassium retention, and salt substitutes contain potassium, creating a dangerous hyperkalemia risk

Option a is correct because spironolactone is a potassium-sparing diuretic that blocks aldosterone and retains potassium, and most salt substitutes contain potassium chloride, which can cause dangerous hyperkalemia. Option b is incorrect because while spironolactone promotes some sodium excretion, the primary dangerous interaction with salt substitutes is elevated potassium levels, not critically low sodium. Option c is incorrect because salt substitutes do not increase fluid retention when combined with spironolactone; the concern is specifically about the potassium content of the substitutes, not a fluid issue. Option d is incorrect because spironolactone promotes sodium excretion rather than sodium absorption, and the warning about salt substitutes is specifically about their potassium content, not sodium interactions.

Correct Answer: Administer naloxone and reassess respiratory status after two to three minutes

Option d is correct because a respiratory rate below twelve indicates opioid-induced respiratory depression, requiring immediate administration of naloxone with reassessment within two to three minutes for response. Option a is incorrect because lowering the infusion rate does not reverse opioid that is already on board; the patient is in active respiratory depression requiring pharmacological reversal, not dose adjustment. Option b is incorrect because repositioning addresses comfort, not opioid-induced CNS and respiratory depression; the priority is pharmacological reversal with the appropriate antidote immediately. Option c is incorrect because notifying staff and documenting are secondary actions; a patient with a respiratory rate of nine and sedation requires immediate pharmacological intervention before any other step.

Correct Answer: Increase fluid and fiber intake and consider a preventive stool softener for constipation

Option b is correct because opioids slow gastrointestinal motility, making constipation a predictable and universal long-term side effect that must be proactively managed with hydration, fiber, and stool softeners. Option a is incorrect because opioids like oxycodone have no anti-inflammatory properties, and combining with acetaminophen without provider guidance risks exceeding the safe daily limit of four grams. Option c is incorrect because avoiding all physical activity is not appropriate; gentle mobility is encouraged though fall precautions are needed due to opioid-induced sedation and orthostatic hypotension. Option d is incorrect because while some tolerance to opioid side effects may develop, the timeline varies per patient; notably, constipation often persists and does not resolve with tolerance like nausea can.

Correct Answer: Clarify the order with the provider and verify the existing patch is removed before applying a new one

Option c is correct because the old fentanyl patch must always be fully removed before applying a new one; overlapping patches deliver dangerously excessive fentanyl concentrations that can cause fatal respiratory depression. Option a is incorrect because applying a second patch without removing the first significantly increases fentanyl delivery and creates a life-threatening overdose risk regardless of which body site is selected. Option b is incorrect because temporarily removing and then reapplying both patches still results in two simultaneous patches delivering overlapping drug levels; only one patch should be worn at any given time. Option d is incorrect because while pharmacy consultation is helpful, the immediate safety priority is clarifying the order and confirming patch removal before any new patch administration occurs.

Correct Answer: Naloxone has a shorter half-life than most opioids and requires repeat dosing as levels drop

Option a is correct because naloxone has a half-life of one to two hours, which is shorter than many opioids; re-sedation occurs as naloxone wears off before the opioid is fully metabolized, requiring additional doses. Option b is incorrect because re-sedation after initial improvement is a pharmacokinetic issue related to naloxone's short duration of action, not a route or technique error during the initial administration. Option c is incorrect because opioid tolerance affects the amount of opioid needed for analgesia, not naloxone's ability to reverse receptor-level opioid toxicity in an acute overdose emergency. Option d is incorrect because waiting for complete unresponsiveness before giving a second dose delays critical intervention; reassessment every sixty minutes with readiness to redose is the correct standard practice.

Correct Answer: The patient has underlying pulmonary disease and is within twenty-four hours post-surgery

Option d is correct because the greatest documented risk factors for opioid-related death are underlying pulmonary disease such as COPD combined with being within twenty-four hours of surgery, significantly elevating respiratory depression risk. Option a is incorrect because age forty with physical fitness represents a lower-risk profile; advanced age over seventy and pulmonary conditions are the primary documented risk factors for opioid fatality. Option b is incorrect because mild constipation is a manageable expected opioid side effect, not a risk factor for opioid-induced respiratory failure or other life-threatening complications. Option c is incorrect because prior tolerance of codeine suggests some opioid exposure, but it does not protect against fentanyl's potent respiratory depression, especially given the patient's compromised pulmonary baseline.

Correct Answer: Draw up the clear regular insulin first, then draw the cloudy NPH insulin second

Option b is correct because the rule for mixing insulins is clear before cloudy; drawing regular insulin first prevents contamination of the clear vial with NPH additives that could alter its pharmacokinetics. Option a is incorrect because drawing NPH first risks contaminating the regular insulin vial with NPH's modifying agents, which could change the onset and duration of the regular insulin unpredictably. Option c is incorrect because while NPH and regular insulin can be mixed, the order absolutely matters; clear must always precede cloudy to prevent cross-contamination between the two separate vials. Option d is incorrect because NPH and regular insulin are compatible and can be drawn into one syringe when ordered together; using separate syringes increases injection burden unnecessarily for the patient.

Correct Answer: I should take my insulin about fifteen minutes before my meal or right after starting to eat.

Option c is correct because insulin lispro is rapid-acting with onset within fifteen minutes, requiring administration immediately before or right after starting a meal to appropriately match the postprandial glucose rise. Option a is incorrect because administering rapid-acting insulin two hours before eating would cause peak insulin effect well before glucose rises from the meal, creating a serious and dangerous hypoglycemia risk. Option b is incorrect because taking rapid-acting insulin after finishing a full meal risks a timing mismatch between peak insulin effect and glucose absorption, increasing the likelihood of hypoglycemia. Option d is incorrect because insulin lispro is a mealtime coverage insulin taken to manage carbohydrate intake at each meal, not a correction dose reserved only for elevated pre-meal blood glucose readings.

Correct Answer: Glargine is a long-acting peakless insulin with a unique pH that is disrupted when mixed, altering its absorption profile

Option a is correct because insulin glargine has a unique acidic pH that produces peakless twenty-four-hour action; mixing it with other insulins alters that pH, disrupting its sustained steady-release mechanism entirely. Option b is incorrect because the restriction on mixing glargine is not dependent on care setting; it applies universally and is based on its chemical properties, regardless of who supervises the administration. Option c is incorrect because insulin glargine has no peak at all, which is its defining pharmacokinetic feature; attributing a twelve-hour peak to glargine reflects a fundamental misunderstanding of long-acting insulin. Option d is incorrect because insulin glargine is exclusively subcutaneous; only regular insulin can be given intravenously, making this claim a fundamental pharmacological error about insulin administration routes.

Correct Answer: Hold metformin forty-eight hours before the contrast procedure to prevent lactic acidosis

Option d is correct because contrast dye can temporarily impair renal function, and metformin combined with reduced kidney clearance dramatically increases the risk of accumulation and life-threatening lactic acidosis. Option a is incorrect because continuing metformin through contrast administration is unsafe; the contrast-related reduction in renal clearance allows metformin to accumulate, creating dangerous conditions for lactic acidosis. Option b is incorrect because doubling metformin before a procedure requiring contrast and possible NPO status would dramatically increase lactic acidosis risk and cause dangerous blood glucose instability. Option c is incorrect because switching to insulin for the entire hospital stay is not standard protocol; the primary concern is specifically the forty-eight-hour contrast window, not the full admission period.

Correct Answer: Administer the glucagon intramuscularly or subcutaneously, then provide oral carbohydrates once the patient can safely swallow

Option b is correct because glucagon emergency kits are designed for IM or subcutaneous injection in unconscious hypoglycemic patients, followed by oral carbohydrates once they can swallow safely without aspiration risk. Option a is incorrect because nothing should ever be given orally to an unconscious patient due to aspiration risk; glucagon must be injected when the patient cannot take anything safely by mouth. Option c is incorrect because waiting for consciousness before giving glucagon defeats its entire purpose; it is specifically designed to restore consciousness by stimulating glycogen breakdown when oral intake is impossible. Option d is incorrect because glucagon is not available in sublingual tablet form; it is a powder reconstituted for injection, and placing anything under the tongue of an unconscious patient risks aspiration.